KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Return on Equity (2020 - 2025)

Aurinia Pharmaceuticals' Return on Equity history spans 6 years, with the latest figure at 0.61% for Q4 2025.

  • For Q4 2025, Return on Equity rose 59.0% year-over-year to 0.61%; the TTM value through Dec 2025 reached 0.61%, up 59.0%, while the annual FY2025 figure was 0.6%, 58.0% up from the prior year.
  • Return on Equity reached 0.61% in Q4 2025 per AUPH's latest filing, up from 0.22% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.61% in Q4 2025 to a low of 0.6% in Q3 2021.
  • Average Return on Equity over 5 years is 0.16%, with a median of 0.2% recorded in 2023.
  • Peak YoY movement for Return on Equity: dropped -21bps in 2021, then soared 59bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.47% in 2021, then skyrocketed by 44bps to 0.26% in 2022, then rose by 22bps to 0.2% in 2023, then soared by 107bps to 0.02% in 2024, then soared by 3936bps to 0.61% in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Return on Equity are 0.61% (Q4 2025), 0.22% (Q3 2025), and 0.18% (Q2 2025).